P50-5 Efficacy and Safety of CBDCA/ETP/ICI Combination Therapy for Extensive-Stage Small Cell Lung Cancer in Elderly Patients

Platinum and etoposide (ETP) combined with PD-L1 inhibitor is considered the first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). However, reports on this regimen in combination with immune checkpoint inhibitors (ICIs) in the elderly are lacking. We evaluated the efficacy and safety of carboplatin (CBDCA)/ETP/ICI combination therapy for patients with ES-SCLC aged ≥ 71, in our hospital.